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Cytochrome P450 (CYP) enzymes catalyze the generation of reactive species capable of binding
with cellular macromolecules, leading to acute and delayed toxicity. Since individual CYP forms
differ markedly in their substrate preferences and regulation, the expression profiles of CYP
in various cell types are important determinants in tissue-specific toxicity. The highest
concentrations of most forms of CYP are found in liver, but they are also present in many
extrahepatic organs. Liver is also a target organ in which CYP-mediated activation and toxic
outcome have been most convincingly linked. Prime examples are paracetamol-induced
hepatotoxicity and aflatoxin Bl-associated hepatic cancer. In contrast to liver, most extrahepatic
tissues are composed of multiple cell types, which make experimental approaches difficult. Also
the low abundance of individual forms is a challenge in the study of extrahepatic CYP-related
toxicity. Recent years have witnessed the emergence of molecular biological techniques, e.g.,
reverse transcriptase-polymerase chain reactions, which facilitate the study of low abundant CYP
forms in human tissues. Nevertheless, in the end we need definite information on the expression
of activity, and for this purpose enzyme-specific substrates, reactions, and inhibitors and other
methods to detect proteins and associated activities are needed. In humans, it is important to
measure activities of specific enzymes in vivo. For this purpose, two approaches are currently
available. Metabolism and/or elimination of enzyme-specific drugs can be employed. In cases in
which genetic background determines the presence or absence of a specific enzyme,
phenotyping and genotyping tests can be devised, e.g., for CYP2D6 (debrisoquine hydroxylation)
polymorphism. Environ Health Perspect 105(Suppl 4):767-774 (1997)
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Introduction
The concept ofmetabolic activation, i.e.,
formation ofreactive metabolites, has been
a very useful paradigm in chemical car-
cinogenesis and chemical-induced toxicity
for three major reasons: first, it has pro-
vided a mechanistic basis for understand-
ing the initial action ofstructurally diverse
carcinogens and toxicants; second, it has
provided an explanation for the binding of
many chemical compounds to DNA and
other macromolecules; and third, it has
been a crucial bit ofknowledge in the cre-
ation ofshort-term genotoxicity and other
toxicity tests for the prediction of toxic
reactions, including chemical carcinogene-
sis. Although this paradigm is overwhelm-
ingly accepted, the exact details are often
lacking. For example, most studies on
metabolic activation have been conducted
with liver preparations with an abundant
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assortment ofboth activating and inacti-
vating drug-metabolizing enzymes. The
expression ofcrucial enzymes at the site of
action, other than liver, has not often been
adequately studied.
Formation of reactive metabolites is
catalyzed principally by the so-called drug-
or xenobiotic-metabolizing enzymes,
but some activating reactions are catalyzed
also by enzymes principally involved in
endogenous metabolism. The most impor-
tant group ofactivating enzymes is the large
P450 (CYP) "superfamily" (1) catalyzing
oxidative (and sometimes reductive) reac-
tions; but practically all conjugating
enzymes are also capable offorming reactive
metabolites from a few selected substrates,
e.g., reactive glutathione conjugates are
generated ofsomehalogenated compounds.
The prevailing opinion thus far has
been that for a given compound, metabolic
activation is rather difficult to predict
because it depends on both the structure of
the substrate and the specific enzymes
involved. Another hindrance in the predic-
tion ofconsequences ofmetabolic activa-
tion has been the lack ofexact knowledge
about endogenous and exogenous factors
affecting the level and balance ofenzymes.
However, recent studies on the activation
ofnumerous potent genotoxins and poten-
tial carcinogens by human liver enzymes
demonstrate that a relatively small number
ofCYP forms primarily activate genotoxins
and other toxicants. Such studies show
promise in that it may be possible in the
future to predict an individual's ability
(even the inherited ability) to activate
specific toxins.
One of the crucial endogenous factors
is polymorphic variability ofvarious CYP
forms (Table 1), which is ofconsiderable
clinical importance but which may also be
significant in individual susceptibility to
chemical carcinogens and other toxic sub-
stances. However, the significance ofCYP
polymorphisms in the expression and
metabolic activation oftoxic substances in
target tissues other than liver has not been
elucidated to any great degree although,
hypothetically, variant alleles ofstructural
genes should be similarly expressed in all
expression-competent tissues.
This article surveys the present status of
the field in terms oftissue-specific expres-
sion, metabolism ofsome toxicants, and
especially the methodologies that measure
their parameters while focusing upon
CYP enzymes.
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Table 1. Polymorphisms of human CYP genes.
Gene Defective allele Activity Remarks
CYPlA1 11e462Val ? Ethnic variation
CYP1A2 ? Variable phenotypes
CYP2A6 vl: Leul6OHis 0 Ethnic variation
v2:several changes 0 Ethnic variation
CYP2B6 ? ? Low expression
CYP2C9 11e359Leu Down Ethnic variation
CYP2C19 3 null alleles 0 Ethnic differences
CYP2D6 Numerous (about25) Up, down, 0 Ethnic differences
CYP2E1 5', 3', intron ? Ethnic variability
CYP2F1 ? ? ?
CYP3A4 2AA changes ? Rare
CYP3A5 ? 0 Incidence unknown
CYP3A7 ? ? ?
CYP4B1 ? ? ?
Significance of Tissue-specific
Expression of CYPs
The potential role ofselective presence of
CYP forms in different tissues can be
derived from many forms that are known to
generate reactive metabolites in situ from a
number of xenobiotics. Thus, selective
expression of CYP forms possibly con-
tributes to tissue-specific damage caused by
xenobiotics. Figure 1 is a simplified scheme
illustrating the two main possibilities. Ifthe
metabolite formed in the liver or any other
tissue is stable, it can be transported locally
or through the bloodstream to distant sites,
where it can produce the effects. The other
possibility is that the parent compound
undergoes metabolic activation in the target
tissue itself, and that the reactive metabo-
lites formed attack the macromolecules of
the activating cell. Given the highly reactive
nature of many oxidized compounds, the
latter possibility appears more plausible in
most instances. Nevertheless, examples of
the first possibility include monocrotaline-
induced lung damage, neurotoxicity caused
by tetraethyl lead and n-hexane, as well as
testis toxicity elicited by 2-methoxyethanol
(2). Ultimate toxicity in the target tissue
depends on several factors, including the
amount of reactive intermediates formed,
the extent of detoxication processes, and
the efficiency and fidelity ofrepair systems,
such as DNA-repair enzymes.
A heavily studied aspect oftissue distri-
bution ofxenobiotic metabolizing enzymes
relates to target organ selectivity ofchemi-
cal carcinogens. A large proportion ofthe
known or suspected carcinogens require
metabolic activation; many carcinogens
exhibit marked tissue specificity, with a
given compound producing cancers at some
sites and no effects at others. There is thus a
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Parent - - .Toxic - ''
compound metabolite Inactive
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Blood
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Figure 1. Possible pathways of a xenobiotic and its toxic metabolites in the body. After absorption, the xenobiotic
is distributed throughout the body through the bloodstream. The parent compound, if hydrophobic enough, can
travel freely in different tissue compartments. Xenobiotic-metabolizing enzymes act in concert to convert the
parent compound to a water-soluble metabolite. Toxic metabolites can be formed in virtually any tissue, but the
main bulk of metabolites is usually generated in liver. Tissue-specific toxicity depends partially on the amount of
metabolizing enzymes present in target tissues. A reactive metabolite can migrate to sites distant from the tissue
of origin. For example, reactive metabolites formed in liver can cause toxic effects in lungs.
clear urgency in understanding tissue-
specific activation mechanisms. Many
human CYP forms are known to be able to
activate numerous procarcinogens. The
inactivation pathways by CYP and conju-
gating enzymes are also being unraveled
(3-6). The genetic variations in xenobiotic-
metabolizing enzymes in relation to cancer
have been reviewed in several articles (7-10).
Methods of Studying the
Expression of CYP Forms
A large number of chemical, biophysical,
biochemical, and molecular biological
methods have been used in P450 research.
For example, detection ofactivity, i.e., cat-
alytic capability in vitro, uses substrates or
reactions with tissue preparations, e.g.,
lung or liver microsomes and lymphocytes.
In vivo detection may use probe drugs
such as caffeine or debrisoquine and
endogenous substances such as 6,-hydrox-
ycortisol. Detection ofexpression (message
and/or protein) may be accomplished
using Western (protein) or Northern blot
(mRNA); reverse transcriptase (RT)-poly-
merase chain reaction in tissue RNA sam-
ples, which may be either qualitative or
quantitative; in situ hybridization; or
immunohistochemistry. Detection of
genomic status (gene structure, alleles)
uses restriction fragment length polymor-
phism (RFLP) or Southern blot (PCR on
DNA). Note that the development of
methodologies has made use ofliver, with
its wide and abundant assortment ofP450
and other drug-metabolizing enzymes.
The application ofmany ofthese methods
and approaches to other target tissues
faces a number of problems and pitfalls,
including the following:
* low amounts and (possible) lability of
enzymes
* different profiles of CYP and other
enzymes as compared to liver (Table 2)
* unique, tissue-specific enzymes
* tissue-specific regulation of even those
enzymes that are expressed in many
tissues
* tissue heterogeneity (liver 90% hepato-
cytes; lungs > 30 cell types) with cell-
specific assortments ofenzymes
* isolation ofcell organelles standardized
for liver; not necessarily applicable to
other tissues.
Furthermore, after the demonstration
ofa specific CYP enzyme in a given tissue,
we need a variety ofapproaches to link the
activitywith the toxic outcome.
There arebasicallyfivegroups ofmethods
to study the expression ofindividual CYP
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Table 2. Expression ofxenobiotic-metabolizing CYP forms in human tissues.
CYP
Organ/tissue lAl 1A2 2A 2B 2C 2D6 2E1 2F1 3A 4B1 4A11
Liver ++ +++ +-+l +++ +++ +++ +++ 0 +++ 0 0
Lung +++ ND ND +++ ND ND ++ +++ +++ +++ ND
Small intestine ++ ND ND ND + + ND ND +++ ND ND
Skin ++ ND ND ND ND ND ND ND + ND ND
Kidney + ND ND ND ND ND ND ND +++ ND +++
Brain ++ ND ND ND + ++ + ND ++ ND ND
Vascular endothelium ++ ND ND ND ND ND ++ ND ++ ND ND
Lymphocytes +++ ND ND ND ND ND ND ND ND ND ND
Mammary gland +++ ND ND ND ND ND ND ND ND ND ND
Placenta +++ 0 0 0 0 0 + + ++ +++ ND
ND, not enough data available; +++, strong evidence, based on demonstration of CYP mRNA and/or protein (and
often on activity); ++, tentative evidence, based on demonstration of mRNA, catalytic activities or cross-reactions
with anti-CYP antibodies, verified in several laboratories; +, preliminary evidence, based on catalytic activities or
cross-reactions with antibodies; 0, not present. It is likely that many laboratories have obtained negative data that
has not been published, and that many of these isoforms will eventually be found. Modified from Raunio (34).
Table 3. Diagnostic substrates and inhibitors of human
CYP forms.
Substrate
7-Ethoxyresorufin
Phenacetin
Caffeine
Coumarin
6-Aminochrysene
Cyclophosphamide
Taxol
Tolbutamide
S-Mephenytoin
Debrisoquine,
sparteine,
dextromethorphan
Chlorzoxazoneb
Skatole
Testosterone,
nifedipine
Inhibitor
7,8-Benzoflavonea
Furafylline, fluvoxamine
Diethyidithiocarbamate,
8-methoxypsoralen
Not known
Quercetin
Sulfaphenazole
Tenoposide?
Quinidine
Diethyldithiocarbamatec
Not known
Troleandomycin,
gestodene
Compiled from Pelkonen and Breimer ( 16) and
Pelkonen et al. (18). 'Also inhibits CYP2C9 and CYP3A4
(66).bAlso metabolized by CYPlAl (67). cAlso inhibits
CYP2A6 (66).
forms: determination of enzyme catalytic
activities in tissue samples using form-selec-
tive diagnostic substrates and inhibitors,
methods that can also be applied to the in
vivo situation under certain constraints;
purification and reconstitution of CYP
proteins from different tissues; utilization
of antibodies in various immunodetection
protocols; cloning and sequencing of CYP
cDNAs and their use as probes in various
types of mRNA analysis; and RT-PCR,
often combined with the use of specific
restriction enzymes, RFLP.
A new and exciting approach is to
generate knock-out mice in which specific
CYP structural genes or genes encoding
regulatory receptor proteins are disrupted
by targeted mutations (11). These mice,
lacking the proper function ofthe disrupted
gene, serve as excellent models in the study
ofthe role ofthese genes in organ develop-
ment and, ifthe mutations are compatible
with life, also in the various toxicities
caused by metabolized xenobiotics (12).
Diagnostic Substrates andInhibitors
Numerous chemicals have been tested as
substrates or inhibitors of CYP forms in
experimental animals and humans
(13-16). Table 3 lists some of the best
established form-specific substrates and
inhibitors of human CYPs. Substrates or
inhibitors are very seldom, if ever, com-
pletely enzyme specific; usually a single
substrate can be metabolized by several
CYP forms, and a single form can accept
several substrates. On the other hand, at
low concentrations of several substrates,
enzyme kinetics often favor a single form
being the primary catalyst ofmetabolism.
A number of compounds have been
found to inhibit P450-mediated metabolism
ofother chemicals (14,17). Inhibition can
be either reversible or irreversible depending
upon the chemical. Irreversible inhibitors
binding covalently to P450 enzymes are
often called mechanism-based or suicide
inhibitors. These are often more form spe-
cific than reversible ones because the
enzyme must initially accept the inhibitor as
a substrate, which is then metabolized to a
reactive species (13,14).
Currently, with the aid of known
enzyme-specific reactions and purified and
heterologously expressed human enzymes,
it is possible to unequivocally assign relative
inhibitor affinities to a series of related
enzymes. A selection ofinhibitors listed in
Table 3 is claimed to express at least a
degree ofenzyme specificity, which might
be useful in the assignment of metabolism
of any new substance to each specific
enzyme. Specificity is seldom, if ever,
absolute; rather, an inhibitor shows variable
affinities to different enzymes. However, for
practical purposes, one or two orders of
magnitude difference is probably enough
for a compound to be useful as a specific or
diagnostic inhibitor.
In human studies, for obvious reasons, it
would be very useful to have a substance
that could be used to measure the activity of
an enzyme in vivo (a probe drug). However,
such an in vivo probe has to fulfill more
stringent conditions than an in vitro sub-
strate (18). Also the validation ofan in vivo
probe, which has to be performed in human
subjects-healthy volunteers or patients-is
a demanding and cumbersome task and has
been accomplished only for a handful of
substances. The most thoroughly validated
probes are those for polymorphic CYP
enzymes (such as debrisoquine or mepheny-
toin) because they display phenotypically
separable, pharmacokinetically defined
groups and the correspondence between
genotype and phenotype is often relatively
direct, e.g., lack ofan enzyme shows up as a
poor metabolizer.
An example ofan in vivo probe drug is
caffeine; although several distal metabolites
are produced, these can be grouped under
three enzymes (CYP1A2, NAT2, and xan-
thine oxidase) and consequently can be
used as probes for the respective enzyme.
However, despite the wide use ofcaffeine as
an in vitro and in vivo probe, concern still
exists about the uncritical use ofcaffeine
metabolites as probes (19).
P450 Protein Purification
Comprehensive reviews are available about
this issue (20,21). Approximately 10 human
hepatic CYP proteins in families 1 to 4
have been purified to a degree at which
unequivocal form assignment is possible. It
is obvious that these forms represent the
most abundant ones present in human liver
and that forms expressed at low levels in
the liver or other tissues cannot be readily
purified to homogeneity.
Antibodies and
Immunochemical Methods
A large number of polyclonal and mono-
clonal antibodies have been developed
against purified animal and human CYP
forms, and many of these are commer-
cially available (21,22). A novel and
promising technology is the production of
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Form
CYPlAl
CYP1A2
CYP2A6
CYP2B6
CYP2C8
CYP2C9
CYP2C19
CYP2D6
CYP2E1
CYP2F1
CYP3A4
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monospecific antibodies against synthetic
CYP peptides (23,24). In general, mono-
clonal antibodies are epitope specific and
thus yield more precise information than
polyclonal antibodies. Use ofmonoclonal
anti-CYP antibodies in qualitative and
quantitative detection of individual CYP
forms has recently been reviewed (21). The
advantage of using polyclonal antibodies is
that they are usually inhibitory to the tar-
get enzyme. Anti-CYP antibodies are used
in several techniques as probes to detect the
presence of individual CYP forms. The
basic methods are catalytic activity inhibi-
tion, immunoblotting (Western blotting)
and immunohistochemistry. The main
advantage ofimmunohistochemistry is that
with this technique the distribution ofthe
detected antigen in tissues can be eluci-
dated. This is an important feature in
extrahepatic tissues, which often consist of
several parenchymal cell types mixed with
supporting cells.
Current immunohistochemical tech-
niques have the sensitivity and resolution to
locate specific cell types containing identifi-
able CYP forms, even in tissues with a low
overall P450 content (25). The lung is the
best example ofa complex tissue in which
substantial progress has been made with
immunohistochemical approaches in the
localization ofseveral distinct CYP forms in
various cell types. No other method, exclud-
ing in situ hybridization, could have yielded
such precise information. A comprehensive
review on the use ofimmunohistochemical
methods in pulmonary P450 research
is available (26).
cDNACloni
To characterize the amino acid sequence of
almost any protein, the best approach is to
determine the nucleotide sequence of its
cDNA. cDNA and genomic cloning of
CYP forms have made it possible to con-
struct the CYP superfamily (1). The molec-
ular biology ofCYPs has been reviewed by
Gonzalez (27,28). The cDNAs produced
can be employed for various types of
mRNA detection protocols, such as the
Northern blot and dot-blot methods. In
situ hybridization, a method that combines
the virtues of histochemistry and RNA
hybridization techniques, has much poten-
tial for studying expression patterns in
extrahepatic tissues. The basic steps ofthis
technique are preparation and fixation of
tissue slices, treatment to render them per-
meable to nucleic acid probes, hybridiza-
tion with radioactive DNA or RNA probes,
and autoradiography.
As in immunohistochemistry, the main
advantage of in situ hybridization is that
the distribution of the target molecule in
the tissue under study can be evaluated.
This is especially helpful in tissues that are
composed of several types of cells. This
technique is rather laborious and sensitive,
and there is no consensus on the optimal
handling protocols for human tissues.
However, some groups have recently
obtained reproducible results with human
liver and extrahepatic tissues (29,30).
RT-PCR
The use of PCR-based methods is rapidly
increasing in the study ofgene expression,
and several novel PCR-based methods are
now available to measure the amount of
specific mRNAs in a quantitative manner
(31). The basic protocol to measure gene
expression by PCR involves synthesis of
cellular mRNA to cDNAwith reverse tran-
scriptase, amplification ofthe cDNA tem-
plate using gene-specific primers, and
detection ofthe amplification product.
Several groups have used this method
to assess the expression of CYPgenes in a
qualitative manner, i.e., to screen whether
a given CYP form is expressed or not in
the tissue under study. In the first report
in which RT-PCR was used for detection
of CYP forms in humans, CYPlAl mes-
sage was found in several tissues, including
liver and lung (32). Hakkola et al. (33)
assessed by qualitative RT-PCR the
expression of all known CYP forms in
families CYP1 to CYP4 in human liver.
The results correlated well with known fea-
tures of CYP expression (Table 2). The
RT-PCR approach is being increasingly
used to detect CYP form mRNAs in several
extrahepatic tissues (34).
Quantitative RT-PCR technique for
measuring CYPlAI expression in human
lymphocytes was applied first by Vanden
Heuvel et al. (35). An artificial recombi-
nant mRNA (rcRNA) containing the same
primer annealing sites as CYPlAI was used
as an internal standard. The rcRNA is
added to the cDNA synthesis reaction
together with the test RNA, and the ampli-
fied products are distinguished by their dif-
ferent sizes in gel electrophoresis. After
optimization, this approach yields an
absolute quantitation of the amount of
CYPlAl mRNA present in the sample.
Treatment of lymphocytes with 10 nM
2,3,7,8-tetrachlorobenzo-p-dioxin
(TCDD) resulted in a 20-fold increase in
the amount ofCYPlAI mRNA, which is
verylow in uninduced lymphocytes (35).
The PCR methodology is also central
in the development ofgenotyping assays to
detect variant alleles of CYP genes. The
best validated methods are those that
detect the most common variant alleles of
CYP2D6(36,37) and CYP2C9 (38). The
latest addition to the genotyping assays is
the PCR-based method to detect variant
CYP2A6alleles (39).
Tissue-specific Expression
of CYP Forms and Examples
ofTissue-specific Toxicity
When we are trying to link metabolic
activation and tissue toxicity in a given tar-
get tissue, the following prerequisites have
to be met:
* The enzymes necessary for the activa-
tion have to be expressed in the target
tissue, or we have to demonstrate that
the reactive intermediate formed in
another tissue is transported to the site
ofaction.
* We need to demonstrate that the tissue
preparations or isolated cells are able to
catalyze the activation reaction.
* We should show that a tissue sample
isolated from a human being exposed
to a compound under study contains
appropriate bound metabolite(s).
Alternatively, appropriate animal exper-
iments should give a basis for extrapola-
tion to the human situation, especially
if it is not possible to obtain appropri-
ate human tissue samples.
* A logical and biologically plausible
sequence of events from exposure,
metabolic activation, covalent binding,
biochemical changes, and overt tissue
damage should be demonstrated.
Naturally, when we are dealing with
humans, it is seldom possible to establish an
unequivocal sequence of events; but we
should try to demonstrate at least some of
the necessary factors, e.g., the expression of
activating enzyme(s) in the target tissue. A
compilation of CYP expression in various
tissues is presented in Table 2. Furthermore,
some better known examples ofchemical-
induced tissue toxicities are shown in Table
4. In the next few paragraphs, we summa-
rize examples ofCYP expression in potential
target tissues.
Liver
Perhaps the most compelling case is provided
by paracetamol-induced liver toxicity in
which it is possible to construct the logical
and plausible sequence of events and also
to delineate factors enhancing and oppos-
ing toxicity. With most other toxicants,
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Table 4. Some examples of CYP-mediated tissue
toxicities.
Chemical(s)
Paracetamol
Aflatoxin B1
Nitrosamines
Haloalkanes
Tacrine
4-lpomeanol
Skatole
Benzidine
Cyclophos-
phamide
Benzene
Dapsone
Target/reaction Activating enzyme(s)
Liver/necrosis CYP2E1, CYP1A2
Liver/cancer Multiple
Liver/cancer CYP2E1, CYP2A6?
Liver/necrosis CYP2E1
Liver/toxicity CYP1A2
Lung/necrosis CYP3A
Lung/necrosis CYP2F1
Bladder/cancer CYP1A2?
Bladder/cystitis Multiple
Bone marrow/ CYP2E1
leukemia
Erythrocytes/ CYP3A4
methemoglobinemia
and especially with those causing toxicity
in extrahepatic tissues, it is not possible to
construct such a logical and well-researched
scheme, but with paracetamol-induced
toxicity, the following discrete steps can
be traced:
* Paracetamol is activated into reactive
intermediate (quinoneimine) by
CYP2E1, CYP1A2, and CYP3A4 both
in vitro, ex vivo, and in vivo.
* In normal doses, main metabolic path-
ways (glucuronidation, sulfoconjuga-
tion) lead to inactive products.
* Active metabolite is inactivated by glu-
tathione, partly catalyzed by glutathione
S-transferase.
* Formation ofactive metabolite is inhib-
ited by known CYP form-specific chem-
ical inhibitors and antibodies, as well as
byglutathione precursors or derivatives.
* Activation is enhanced by ethanol and
phenobarbital pretreatment.
* Active metabolite is covalently bound
to hepatic proteins.
* Several possible and plausible cellular
events may lead from covalent damage
to overt cellular damage and necrosis.
Another established case is the associa-
tion between activation and covalent bind-
ing of numerous hepatocarcinogens (e.g.,
aflatoxin B1) and the development ofliver
cancer. Relatively good correlation exists
between DNA adducts and carcinogenic
potency ofseveral hepatocarcinogens. P450
enzyme-specific activation reactions have
been elucidated for many of these com-
pounds, making it possible, for example, to
predict the influence of appropriate P450
polymorphisms on cancer risk (40,41).
Lung
Pulmonary tissue is the first to encounter
all inhaled xenobiotics. Several mechanisms
have developed in the lung to minimize
the entry of foreign compounds into the
systemic circulation, including the presence
of P450 and conjugating enzymes in the
various pulmonary cell types. The lung is a
target for tobacco smoke-induced lung
cancer, one ofthe best characterized chemi-
cal toxicities in humans. Several procarcino-
gens present in tobacco smoke are, after
metabolic activation, capable of inducing
and promoting neoplastic transformation in
the lung cells (42).
The human lung has an extensive
complement ofxenobiotic-metabolizing
enzymes, the main features ofwhich are
the following:
* 100,000xgpellet (microsomal fraction)
contains little endoplasmic reticulum
* Total P450 spectrum detectable
* Extensive oxidation and metabolic acti-
vation ofPAH compounds
* Heterogeneity in CYP expression
among different cell types
* CYPlAI shown at catalytic activity,
protein, and mRNA levels
* CYPlAl inducible by cigarette smoking
* CYP2B7 and CYP3A5 mRNAs abun-
dantly present
* CYP2F1, CYP4B1 and CYP5 cloned
from human lung cDNA library
* CYP2E1 and CYP3A shown at protein
level
Benzo[a]pyrene and other polycyclic
aromatic hydrocarbons are activated to
DNA-binding metabolites by human lung
tissue and catalytic activities mediated by
members in the CYPIA subfamily are mea-
surable and inducible in the lungs.
More direct evidence for the presence of
cigarette smoke-inducible CYPlAl in lung
was provided by several studies in which
CYPlAl was assessed at the mRNA, pro-
tein, and catalytic activity levels (43,44).
These studies have also demonstrated that
CYPlAI inducibility is higher in patients
with lung cancer than in control subjects.
The observed induction is likely to be Ah
receptor mediated, since the receptor is pre-
sent in lung (45,46). The CYPlAl protein
capable of oxidizing 7,8-dihydroxy-7,8-
dihydrobenzo[a]pyrene to a genotoxic
product has recently been purified from
human lung (6).
An example of selective toxicity based
on metabolic activation in the target tissue
is lung cell death caused by 4-ipomeanol.
This toxin is activated by P450 enzymes in
several cell types in the lung, especially the
Clara cells, whereas only marginal activa-
tion occurs in other tissues (47). Studies
with a panel of heterologously expressed
human CYP forms have shown that meta-
bolic activation of 4-ipomeanol is medi-
ated by CYP1A2 and CYP3A4 (48), a
finding that fits well with the presence of
CYP3A members in the lung (49,50).
Another lung toxin, skatole (3-methylin-
dole), is activated by a lung-specific form,
CYP2F1 (51).
Brain
Considerable attention has been paid to
the role ofenvironmental toxins in the eti-
ology of central nervous system disorders.
In particular, exogenous neurotoxins have
been suggested to cause Alzheimer's and
Parkinson's disease (52). Xenobiotics
entering the central nervous system have to
be very lipophilic to be able to cross the
specialized endothelium ofcerebral blood
vessels (blood-brain barrier). It is thus con-
ceivable that metabolism in blood vessel
endothelial cells, as well as in neuronal and
adjacent support cells, would greatly affect
the toxicity elicited by the xenobiotics
entering the brain.
The role of CYPs in brain may include
such diverse functions as metabolism of
xenobiotics, aromatization ofandrogens to
estrogens, and formation of catechols;
CYPs may also participate in metabolism
of neurotransmitters (53). In rodents,
brain P450 levels are low, but there exist
some hot spots such as olfactory areas,
cerebellum, and brainstem where P450
activities are exceptionally high. The same
type of localization is found in human
brain (54). Demonstration ofthe presence
of P450 in the human brain microvessels
and choroid plexuses (55) opens the ques-
tion ofwhether metabolism in endothelial
cells may regulate the penetration of the
xenobiotics to the brain compartment.
Multiple CYP forms are found in the
brain of rats (56). Several CYP forms are
inducible in the rat brain during preg-
nancy, lactation, and treatment with
P450 inducers, such as ethanol, chlorpro-
mazine, phenobarbital, and nicotine (53).
Information about human brain P450 is
limited and is mainly based on autopsy
material that may not reflect the true in
vivo situation for a number ofreasons. For
example, there may be considerable dis-
crepancy in overall P450 levels among dif-
ferent studies. Localization is probably
extremely nonhomogeneous, and there
may be xenobiotic-metabolizing CYP
forms in subfamilies 1A, 2D and 3A. We
know that steroid-metabolizing CYP forms
are definitively present in subfamilies 11A
and 19. There may also be a possible role
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for CYPs in neurotoxin metabolism, either
in activation or inactivation. Evidence thus
far has been fragmentary and not always
convincing (34).
An especially intriguing case is cerebral
CYP2D6. There are indications for its
presence in distinct regions of human
brain and involvement in detoxification of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), a potent neurotoxin that
causes Parkinson's disease-like symptoms.
MPTP is oxidized to the 1-methyl-4-phe-
nol-pyridinium (MPP+) ion by monoamine
oxidase B (MAO-B) in astrocytes and then
taken into dopaminergic neurons via the
dopamine transporter. CYP2D6, in turn,
oxidizes MPTP into a less active metabo-
lite (52,57). Several studies have demon-
strated that a CYP2D6-poor metabolizer
genotype is connected with a 2- to 3-fold
increased risk of developing Parkinson's
disease, whereas other studies have not
come to the same conclusion (57). The
overrepresentation of CYP2D6-poor
metabolizers in patients with Parkinson's
disease might reflect a reduced capacity to
detoxify ingested MPTP-like neurotoxins.
CYP2D6 is also known to metabolize
several centrally acting drugs (58,59). It is
thus likely that activation and inactivation
ofseveral CNS-acting drugs may take place
at or close to the target neuronal tissues,
adding a new dimension to the kinetics of
these drugs. It is possible that CYP2D6
and other forms may participate in the syn-
thesis and degradation of exogenous and
endogenous neuroactive compounds (53).
Thus, generation ofreactive metabolites or
metabolic disorders in situ may lead to
neurotoxicity or neoplasia.
Leukocytes
Because ofthe abundance and relatively easy
availability ofhuman peripheral leukocytes,
much effort has been devoted to using them
as surrogates for P450 activities in other
tissues. Analogous with several other extra-
hepatic tissues, aryl hydrocarbon hydroxy-
lase (AHH) was the first monooxygenase
activity demonstrated in human leukocytes
and pulmonaryalveolar macrophages (34).
Beginning with the pioneering studies
of Kellerman et al. (60), there was a flurry
of reports on the association between lym-
phocyte AHH activity and cigarette smoke-
induced lung cancer. Many reports
suggested that a relationship exists between
higher AHH inducibility in lymphocytes
and the occurrence of carcinoma of the
lung and other tissues, while other studies
did not find such an association (3,7).
Because ofdifferences between monocytes
and lymphocytes (61), there is concern
about the validity of studies done with
unselected leukocyte fractions. Recent
studies have also demonstrated that the
metabolic activation ofbenzo[a]pyrene in
peripheral leukocytes correlates poorly with
that in lung tissue (62). Recent studies
using both conventional Northern blotting
technique (63) and quantitative RT-PCR
approach (35) for lymphocyte CYPIA]
and Ah receptor expression (45) have not
resolved these discrepancies. It seems that
the expression of CYPlAI may be con-
trolled distinctly in the lung and lympho-
cytes, which consequently may not be
suitable as a surrogate for lung microsomes
concerning the pulmonary activation of
PAHs (62,64).
MammaryGland
As in most other extrahepatic tissues,
oxidative metabolism and activation of
benzo[a]pyrene were first indications of
the presence of P450 in mammary gland.
AHH activities in human mammary epithe-
lial cells and mammary tumors range from
nondetectable to relatively high levels and
are inducible by some aromatic substances
(34). In a study involving 188 patients with
malignant or benign breast tumors, AHH
activity was found to be higher in malignant
than benign breast tumors (65). In addi-
tion, the survival and the disease-free inter-
val of the cancer patients who had low
mammary AHH activity was significantly
longer than with patients having highAHH
activity, suggesting that AHH activity may
reflect the overall malignant potential of
breast cancer.
Using a monoclonal antibody against
rat CYPIA in an immunohistochemical
study, Murray and Burke (25) detected
positive staining in the cytoplasm ofbreast
tumor cells, while no staining occurred in
adjacent normal breast epithelium. Thus,
studies in which either AHH activity or
CYPIA protein were used as indicators
show that the expression of CYPIA mem-
ber(s), most probably CYPlAI, is increased
in cancerous breast cells.
Current Problems and Future
Research Needs
In addition to a paucity ofknowledge of
tissue-specific expression ofdifferent CYPs
(Table 2), some further issues have to be
addressed here.
First, some ofthe hepatic P450s seem
to be liver specific, i.e., they are not found
in extrahepatic tissues. One such form is
CYP1A2, which is the predominant form
of the two CYPIA members in the liver,
although it is quite variably expressed.
CYP1A2 is capable of activating various
carcinogens, which give rise to extrahepatic
tumors. It is possible that CYP1A2 as an
activating enzyme represents a case in
which activation occurs in the nontarget
tissue and reactive products are transferred
to the target tissue.
Another problem is concerned with
the significance of low-level expression of
mRNA in various tissues, i.e., whether it
has any functional or toxicological conse-
quences. Basically here we are faced with
an exceedingly sensitive new methodol-
ogy, RT-PCR. In addition, advances in
immunological detection methods have
made it possible to show low levels ofspe-
cific proteins in tissues and here we have
the same problem as with RT-PCR: what
is the role ofthese low-level proteins?
Use of isolated hepatocytes has been
increasing for mechanistic (and even for
toxicological screening) studies. Although
these cells tend to lose (or sometimes
acquire) properties of importance for the
activation of toxicants, nevertheless it is
expected that hepatocytes will serve as a
useful model in studies ofCYP-expression,
metabolic activation, and induction in the
near future. However, the development of
similar approaches for extrahepatic tissues
faces tougher challenges.
Finally, we have to consider the future
requirements and potential of molecular
biological techniques. In vivo drug probes,
however scientifically appropriate and vali-
dated, are cumbersome and expensive, and
they carry at least some-however small-
risk to the subject. For these reasons it
would be useful to have methods that
would give the same crucial information
with minimal invasiveness. For well char-
acterized and properly validated genetic
polymorphisms (a prime example is
CYP2D6) this has been possible in the
form of DNA-based RFLP and PCR
methods (10,37). It would be useful to
have similar methods to measure, for
instance, the potential inducibility,
although necessarily in this case also the
exposure should be quantitated. The
advances in the understanding of regula-
tion ofdrug metabolizing enzymes should
make it possible to develop such assays in
the not too distant future, or at least to
answer the question ofwhether there are
people who for genetic reasons have vary-
ing responses to inducers or other factors
that affect drug metabolism.
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